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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYHuman pluripotent stem cells (hPSCs) offer the opportunity to generate neuronal cells, including nociceptors. Using a chemical-based
approach, we generated nociceptive sensory neurons from HUES6 embryonic stem cells and retrovirally reprogrammed induced hPSCs
derived from fibroblasts. The nociceptive neurons expressed respective markers and showed tetrodotoxin-sensitive (TTXs) and -resistant
(TTXr) voltage-gated sodiumcurrents in patch-clamp experiments. In contrast to their counterparts from rodent dorsal root ganglia, TTXr
currents of hPSC-derived nociceptors unexpectedly displayed a significantly more hyperpolarized voltage dependence of activation and
fast inactivation. This apparent discrepancy ismost likely due to a substantial expression of the developmentally important sodiumchan-
nel NAV1.5. In view of the obstacles to recapitulate neuropathic pain in animal models, our data advance hPSC-derived nociceptors as a
bettermodel to study developmental and pathogenetic processes in human nociceptive neurons and to developmore specific small mol-
ecules to attenuate pain.INTRODUCTION
Human pluripotent stem cells (hPSCs), i.e., human embry-
onic stem cells (hESCs) and human induced pluripotent
stem cells (hiPSCs), can give rise to functional neurons (re-
viewed in Gage and Temple, 2013). Human peripheral neu-
rons are difficult to differentiate, but a recently published
combinatorial small molecule-based approach was able to
overcome this shortage (Chambers et al., 2012). These neu-
rons express canonical markers of nociceptors, such as
TAC1 (pro-peptide to Substance P), SCN9A (NAV1.7), and
SCN10A (NAV1.8). They exhibit currents mediated by
ASIC, GABAA receptors, HCN1, and KCNQ2/3 (Young
et al., 2014).
Neuropathic pain is a disabling and difficult to treat con-
dition that cannot be adequately mimicked in animal
models. Recently, inherited neuropathic pain syndromes
were linked tomutations in voltage-gated sodium channels
(NAVs) (Lampert et al., 2014), stressing the importance of
TTXr NAVs in neuropathic pain and as targets for novel,
specific pain treatment (Bagal et al., 2014).Stem CellNociceptive stimuli are conveyed by NAVs that comprise
nine different subtypes expressed in human and rodents.
Six are tetrodotoxin-sensitive (TTXs) (NAV1.1 to NAV1.4,
NAV1.6, and NAV1.7), whereas three are resistant to TTX
(TTXr) (NAV1.5, NAV1.8, and NAV1.9). Inherited small
fiber neuropathies (SFN) are, among others, associated
with mutations in NAV1.8 (Faber et al., 2012). NAVs un-
dergo expression changes during development, and pain
syndromes linked to NAV mutations occur at certain pe-
riods in life; while theNAV1.7-linked severe pain syndrome
PEPD (paroxysmal extreme pain disorder) can start in
utero, with symptoms declining during adulthood, the
NAV1.7-linked erythromelalgia has its onset in adoles-
cence, and SFN is observed in older adults (Lampert et al.,
2014). This striking variation in disease onset may be due
to modulation of the mutation phenotypes by co-expres-
sion of different NAV subtypes, but experimental support
for this hypothesis is still missing. Expression and function
of NAVs depend critically on the cellular background (Rush
et al., 2006), sounding a strong note of caution when trans-
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true for nociceptors whose excitability is controlled by a
complex interplay between TTXs and TTXr NAVs. Thus,
there is an urgent need for the availability of human noci-
ceptors to investigate the pathophysiology and pharma-
cology of nociception in an appropriate model.
Even though hPSC-derived nociceptors are a promising
cellular model in pain research, a detailed investigation of
their set of NAV subtypes is still missing. Using hPSC-
derived nociceptors, generated by applying an optimized
protocol (Chambers et al., 2012), we explored the matura-
tional stages of hPSC-derived nociceptors and deciphered
the electrophysiological characteristics of their TTXr
NAVs. Our analysis revealed that the generated neurons
not only express NAV1.8 andNAV1.9, but also the develop-
mentally regulated NAV1.5, suggesting that the derived
neurons represent a specific stage during development.RESULTS AND DISCUSSION
hPSC-Derived Sensory Neurons Express Key
Nociceptor Markers
Using an optimized protocol for small molecule inhibition
(Figure 1A), gained by adapting growth factor concentra-
tions, antioxidant supplementation, and optimized cell
seeding densities of a previously published protocol
(Chambers et al., 2012), we successfully differentiated
hESCs (HUES6 line) and hiPSCs (previously published as
control lines iPSC Ctrl-11 and Ctrl-12) (Havlicek et al.,
2014) into human sensory neurons. The reproducibility
of the relative amount of nociceptors and reduced intraline
variation were obtained when adjusting cell seeding
densities to 85,000–100,000 cells/cm2 (compared with
20,000–40,000 cells/cm2 in Chambers et al., 2012),
lowering the neurotrophic factor concentrations to
20 ng/ml, and supplementing the medium with the anti-
oxidant ascorbic acid.
The generated neurons grow in ganglion-like clusters
(Figure 1B) comparable to those of other mammalian sen-
sory neurons (e.g., rat dorsal root ganglion neurons
[DRGs]). Immunofluorescence stainings indicated the
expression of canonical peripheral markers, such as
BRN3A, PERIPHERIN, and TUJ1 (Figures 1C and 1D). The
expression of the nociceptor-specific capsaicin receptor
TRPV1 (Figure 1E) revealed that the majority of TUJ1-
positive cells harbored nociceptor identity (83% of
TUJ1-positive cells within ganglion-like clusters were
TRPV1 positive). Compared with undifferentiated hiPSCs,
the pan-neuronal NAVs NAV1.1, NAV1.2 and NAV1.6 (cor-
responding to genes SCN1A, SCN2A, and SCN8A) were
upregulated in nociceptors (Figure 1F), indicating the suc-
cessful differentiation into neuronal cells (Catterall et al.,
2005). The expression of genes specific for peripheral sen-306 Stem Cell Reports j Vol. 5 j 305–313 j September 8, 2015 j ª2015 The Asory neurons such as NAV1.7 (SCN9A), the P2X3 receptor
(P2RX3), and TRPV1were upregulated in the differentiated
nociceptors compared with hiPSCs (Figure 1G).
For performing a functional analysis, we tested neuronal
excitability by whole-cell patch-clamp experiments. When
electrically evoked, hPSC-derived nociceptors fired toni-
cally (9 of 29) or phasically (15 of 29) as described for ro-
dent sensory neurons (Figure 1H; e.g., Freisinger et al.,
2013), and only few cells were not electrically active (5 of
29). Consecutive voltage clamp recordings of each cell re-
vealed the characteristic ionic signature of neuronal excit-
ability, with brief NAV-mediated inward currents followed
by sustained outward currents (Figure 1I). TTX (500 nM)
was used to delineate TTXr NAVs in hPSC-derived nocicep-
tors, for which a sample recording is shown in Figure 1J.
TTXr Currents in hPSC-Derived Nociceptors
Of the three known TTXr NAVs, NAV1.8 and NAV1.9 are
expressed in the peripheral nervous system, and NAV1.5
is mainly present in the heart (Catterall, 2012). However,
NAV1.5 is also found in rat DRGs during development (Re-
nganathan et al., 2002).We therefore compared expression
levels of NAV1.5, NAV1.8, and NAV1.9 in hPSC-derived
nociceptors (Figure 2A). Undifferentiated hiPSCs already
showed substantial expression of SCN5A, suggesting that
this channel may play a role during early human develop-
ment. Upon differentiation of hiPSCs into nociceptors,
SCN5A remained present, indicating its importance for
sensory neuron development. We found a substantial
increase in SCN10A (encoding NAV1.8) and SCN11A, en-
coding the slowly gating NAV1.9, confirming that the
differentiated cells acquired a peripheral neuron identity.
The abundance of NAV1.5 and NAV1.9 protein was
confirmed by immunofluorescence stainings (Figure 2B).
We evaluated several NAV1.8 antibodies; however, all failed
to be specific in heterologous expression systems (data not
shown).
We explored whether TTXr NAVs of hPSC-derived noci-
ceptors display the distinct biophysical characteristics. In
whole-cell recordings performed in the presence of
500 nM TTX, 79% of cells displayed substantial fast TTXr
NAV currents with properties similar to those of human
NAV1.8 when heterologously expressed in the neuroblas-
toma cell line ND7/23 (Figure 2C). We focused on fast-
gating NAVs, as currents resembling NAV1.9 were only
weakly expressed (data not shown). Compared with heter-
ologously expressed NAV1.8, voltage dependence of activa-
tion wasmuchmore hyperpolarized in human nociceptors
(Figure 2D), suggesting that either NAV1.8 displays
different gating properties in human nociceptors or that
other NAVs were also involved. In support of the latter,
the voltage dependence of activation of hPSC-derived noci-
ceptors was indeed more similar to that of heterologouslyuthors
Figure 1. Differentiation of hPSCs into Human Nociceptors
(A) Overview of differentiation of human ESCs/iPSCs to nociceptors by LSB + 3i. L = LDN193189; SB = SB431542; 3i = DAPT, SU5402,
CHIR99021.
(B) Bright-field image of a ganglion-like cluster. A nociceptor suitable for patch-clamp experiments is indicated by arrowhead.
(C) Ganglion-like clusters stain for BRN3A (green) and PERIPHERIN (red).
(D) Most cells in clusters co-express b3-TUBULIN (TUJ1, red), PERIPHERIN (green), and BRN3A (blue).
(E) Eighty-three percent of TUJ1-positive cells in clusters also express TRPV1.
(B–E) Scale bars represent 100 mm (B and C), 25 mm (D), and 20 mm (E).
(F and G) mRNA expression levels of neuronal NAVs (F) (nR 4 independent experiments, measured as duplicates) and of typical nociceptor
ion channels (G) (nR 4 independent experiments, measured as duplicates). Error bars indicate the SEM.
(H–J) Functional characterization of hiPSC-derived nociceptors. (H) Current clamp recordings of representative phasically firing (top) and
repetitively firing (bottom) nociceptors, elicited by injection of 100 pA for 500 ms. (I) Representative traces recorded with the indicated
protocol (top) show sodium and potassium currents (bottom). (J) Example trace of voltage clamp recordings before and after addition of
500 nM TTX to the recording solution.
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Figure 2. hPSC-Derived Human Nociceptors Express Three Types of TTXr NAVs
(A) mRNA levels of SCN5A, SCN10A, and SCN11A in hPSC-derived nociceptors in comparison to undifferentiated hiPSCs (nR 4 independent
experiments, measured as duplicates).
(B) Immunofluorescence analysis of hiPSC-derived nociceptors revealed a dotted staining pattern for NAV1.5 and NAV1.9 (scale bars
represent 20 mm).
(C) Top: schematic voltage protocol for recording of voltage-gated sodium currents. Bottom: representative traces of voltage clamp
recordings of HUES6- and hiPSC-derived nociceptors and of heterologously expressed human NAV1.8 and NAV1.5.
(legend continued on next page)
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expressed NAV1.5 than to that of NAV1.8 (Figure 2D;
Table S1).
We focused on fast-inactivation properties, as these are
very distinct between NAV1.5 and NAV1.8 in heterologous
expression systems. As demonstrated in Figure 2E, the
voltage dependence of steady-state fast inactivation of
hPSC-derived nociceptors was hyperpolarized compared
with NAV1.8, and rather in the range of that of NAV1.5.
Nevertheless, Vhalf of fast inactivation of TTXr currents
from hPSC-derived nociceptors was more hyperpolarized
than that of NAV1.5 alone in heterologous systems
(Table S1). This may be due to either the expression of
NAV1.9, or to the cellular background, which was shown
to differentially affect gating of human NAVs (e.g., Rush
et al., 2006).
hPSC-Derived Nociceptors Exhibit an Embryonic-like
Expression Pattern of TTXr NAVs
Our results show that hPSC-derived nociceptors express an
electrophysiologically relevant level of functional NAV1.5.
Rat DRGs are well studied and available for comparison of
the expression patterns of TTXrNAVs during development.
Thus, we performed qRT-PCR experiments on E14–E16 and
P6 rat DRGs. Scn5a was strongly expressed at E14–E16, but
its expression levels declined after birth as expected (Fig-
ure 3A) (Renganathan et al., 2002). mRNA levels of Scn9a
and Scn10a did not change significantly, whereas Scn11a
was strongly upregulated after birth (Figure 3A). Whole-
cell recordings showed fast-activating and -inactivating
currents in DRGs from both E14–E16 and P6 rats, although
current density was significantly lower in E14–E16 cells
(E14–E16 cells: 104.4 ± 29.4 pF, n = 4; P6 cells: 196.2 ±
39.8 pA/pF, n = 21; compare scale bars in Figure 3B). Voltage
dependence of activation of hPSC-derived nociceptors was
more hyperpolarized than that of rat DRGs at both devel-
opmental stages (Figure 3C).
Vhalf of inactivation of all nociceptors was more negative
than that of TTXr currents from P6 DRGs and much closer
to that of E14–E16 DRGs, suggesting that the NAV subtype
expression may be similar to developing sensory neurons.
Fast inactivation of TTXr currents from E14–E16 DRGs
showed two components (Figure 3D), reflecting the expres-
sion of more than one NAV subtype, probably including
NAV1.5. In heterologous expression systems, NAV1.5
shows hyperpolarized fast inactivation compared with
NAV1.8 (Figure 2E). Nevertheless, Vhalf of TTXr fast inacti-
vation in human nociceptors (93.0 ± 2.3 mV; 90,7 ±(D and E) Voltage dependencies of activation (D) and steady-state fa
cells of one experiment), hiPSC-derived nociceptors (diamonds, n = 23
NAV1.5 (squares, n = 8–10 cells of one experiment) and, shown only i
one experiment).
All error bars indicate the SEM.
Stem Cell1.6 mV for HUES6- and hiPSC-derived nociceptors, respec-
tively) is still more hyperpolarized than that of NAV1.5
expressed in ND7/23 cells (79.9 ± 2.4 mV). Also, the
activation Vhalfs differ. This may be due to a differential
regulation of NAV1.5 in human nociceptors compared
with heterologous expression systems.
NAV1.5 is less resistant to TTX than NAV1.8 (IC50 for
NAV1.5: 1–6 mM, for NAV1.8: 46 ± 10 mM; Renganathan
et al., 2002).We took advantage of these diverse resistances
to isolate the NAV1.5 current component from NAV1.8
and NAV1.9. Five mM TTX blocked heterologously ex-
pressed NAV1.5 by more than 65% (67% ± 3.6%), a
concentration at which NAV1.8 was only blocked by
13.1% ± 2.7% (Figures 4A and 4B). The unblocked current
fractions for hPSC-derived nociceptors were 42.5% ± 3.5%
and 43.0% ± 1.5% (hiPSC- and HUES6-derived nocicep-
tors, respectively), very similar to our results for NAV1.5
in heterologous expression systems (33% ± 3.6%; Figures
4B and 4C). These results confirm that our hPSC-derived
nociceptors express a substantial level of functional
NAV1.5.
NAV1.8 is supposed to support higher-frequency firing
(Blair and Bean, 2002), especially due to its more depolar-
ized fast-inactivation properties. TTXr fast inactivation is
enhanced in the humannociceptors investigated here, sug-
gesting that the firing rate may be reduced compared with
mature healthy neurons. It is possible that this prevents
nociceptive malfunction during development and sup-
ports normal development. Mutations in NAVs may inter-
fere with this regulation and cause pain syndromes, such as
PEPD, having its onset sometimes already in utero (Lamp-
ert et al., 2014). Themodel presented here offers a platform
to investigate NAV physiology, and patient-derived noci-
ceptors may be a useful tool to elucidate NAV dysfunction.
In summary, we successfully differentiated human sen-
sory neurons from hPSCs. Our cells express canonical
markers of nociceptors and exhibitmany of their character-
istic electrophysiological properties. hPSC-derived noci-
ceptors have the potential to serve as a model system to
interrogate the physiology and pharmacology of human
TTXr NAVs, which emerged as prime targets for the devel-
opment of new pain treatment.
We find that TTXr currents of these nociceptors are more
similar to those of NAV1.5 than to those of NAV1.8 and
NAV1.9, and the electrophysiological and pharmacological
properties of NAV1.5, especially of fast inactivation, fit well
to that of embryonic rodent DRGs. These data reveal thatst inactivation (E) of HUES6-derived nociceptors (triangles, n = 15
–26 cells), NAV1.8 (circles, n = 10–13 cells of one experiment), and
n (E), co-expression of NAV1.8 and NAV1.5 (triangles, n = 8 cells of
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Figure 3. Expression of TTXr Sodium Channels in Developing rat DRGs
(A) mRNA expression levels of Scn5a, Scn9a, Scn10a, and Scn11a in DRGs of embryonic (E14–E16) and neonatal (P6) rats. Scn5a is
downregulated and Scn11a upregulated (in neonatal DRGs compared with E14–E16 (n = 4, two independent experiments, shown as
technical duplicates).
(B) Bottom: representative traces of voltage clamp recordings of E14–E16 and P6 DRGs in the presence of 500 nM TTX. Top: voltage
protocol.
(C) Voltage dependence of activation of HUES6-derived (triangles, red fits, n = 15) and hiPSC-derived nociceptors (diamonds, blue fits,
n = 26) is shifted toward more hyperpolarized potentials compared with rat E14–E16 DRGs (circles, black fits, n = 13 cells) and P6 DRGs
(squares, black fits, n = 21 cells).
(D) Voltage dependence of steady-state fast inactivation of HUES6-derived (n = 15) and hiPSC-derived nociceptors (n = 23) is shifted
toward more hyperpolarized potentials compared with embryonic and neonatal rat DRGs (n = 4 of 19 cells). Data of HUES6- and hiPSC-
derived nociceptors are the same as shown in Figure 2.
All error bars indicate the SEM.hPSC-derived nociceptors offer a unique opportunity of
modeling developing nociceptors and may mimic in
particular early-onset pain syndromes.310 Stem Cell Reports j Vol. 5 j 305–313 j September 8, 2015 j ª2015 The AThe differentiation of hiPSCs gained from patients
with pain syndromes using this chemical approach
might be a promising tool for the investigation of theuthors
Figure 4. TTXr Currents in hPSC-Derived
Nociceptors Display a NAV1.5-like TTX
Sensitivity
(A) TTXr-current traces for human NAV1.5,
NAV1.8, and hPSC-derived nociceptors prior
to (black) and after (red) application of
5 mM TTX for 1 min. Note the slower current
decay kinetics for NAV1.8.
(B) Relative TTXr currents measured during
application of control or high-dose TTX
(arrow, n = 3–5 cells).
(C) Relative remaining currents after appli-
cation of 5 mM TTX for 1 min (n = 5–6 cells).
All error bars indicate the SEM.development of human sensory neurons carrying distinct
mutations and thus may help to define druggable targets
and to decipher the mechanisms underlying pain in
humans.EXPERIMENTAL PROCEDURES
Generation of Nociceptors from hiPSCs and hESCs
Following Institutional Review Board approval (Nr. 4120: ‘‘Gener-
ierung von humanen neuronalen Modellen bei neurodegenera-
tiven Erkrankungen’’) and informed consent at the outpatient
movement disorder clinic at the Department of Molecular
Neurology, Universita¨tsklinikum Erlangen, Germany, hiPSCs
were derived from a healthy Caucasian individual (previously
referred to as Ctrl-1, Havlicek et al., 2014) with no history of
neurologic disease. Fibroblasts isolated from dermal punch bi-
opsies were reprogrammed by retroviral transduction with
SOX2, KLF4 and c-MYC, and OCT3/4 (Takahashi et al., 2007)
and were tested for pluripotency as described previously (Havlicek
et al., 2014). All experiments with hESCs (HUES6) were carried
out in accordance with the German Stem Cell Act (RKI AZ.
3.04.02/0069). hPSCs were cultured on Matrigel (BD Biosciences)
in mTeSR1 medium (Stem Cell Technologies) and passaged in
clumps.
Nociceptor differentiation was performed with modifications to
Chambers et al. (2012). In brief, hPSCswere seeded as single cells at
a density of 85,000–100,000 cells/cm2 in presence of Y-27632
(Sigma-Aldrich). When cells reached 90%–100% confluence, dual
SMAD inhibition was initiated by 100 nM LDN-193189 and
10 mM SB431542 on days 1–5.
Cells were fed daily, and N2/B27 medium (N2/B27 medium:
DMEM/F12/Glutamax, with N2 and B27 [without VitA]; allStem CellLifeTechnologies) was added in increasing 25% increments every
other day starting on day 4. Three mM CHIR99021, 10 mM
SU5402, and 10 mM DAPT were added on days 2–10. On day 10,
cells were dissociated using TrypLE Express (LifeTechnologies)
and seeded on glass coverslips precoated with polyornithine/lam-
inin (LifeTechnologies) or poly-D-lysine (Sigma-Aldrich). Long-
term neuronal culture medium consisted of N2/B27 medium
containing adjusted growth factor concentrations of 20 ng/ml
human-b-NGF (beta nerve growth factor; R&D Systems), BDNF
(brain derived neurotrophic factor), GDNF (glial-cell-line-derived
neurotrophic factor; both Peprotech), and addition of 200 ng/ml
ascorbic acid (Sigma-Aldrich).Animals and DRG Culture
All animal experiments were performed in accordance with ethical
guidelines established by German animal protection law approved
by the animal protection committee of Regierung Mittelfranken,
Germany. Embryos were removed from Wistar rats sacrificed at
days 14–16 of pregnancy. DRGs were isolated from the embryos
or the P6 rats and pooled into groups for RNA extraction and cell
preparation (as described in Klinger et al., 2012). Cells were loaded
on poly-D-lysine-coated glass coverslips, and experiments were
performed the following day.Culture of Cell Lines and Transfection of ND7/23 Cells
ND7/23 cells were maintained in DMEM (LifeTechnologies),
including 10% fetal bovine serum (FBS), 4.5 g/L glucose, and 1%
penicillin/streptomycin (PAA Laboratories) and transfected with
human NAV1.5-cDNA, NAV1.8-cDNA, or both and GFP, using
Nanofectin transfection reagent (PAA Laboratories). For the stable
NAV1.5-HEK293 cell line, 30 g/ml Zeocin (Biochrom) was added,
and glucose was reduced to 1 g/L.Reports j Vol. 5 j 305–313 j September 8, 2015 j ª2015 The Authors 311
qRT-PCR
RNA from DRGs and hPSC-derived nociceptors cultures was ex-
tracted and reversely transcribed, and PCRs were performed as
previously described, using an Eppendorf realplex4 cycler (Eppen-
dorf; Havlicek et al., 2014) and exon-spanning primers shown in
Table S2. Differences in expression levels were determined by the
DCq method.
Immunofluorescence Stainings
Immunofluorescence stainings were performed as described previ-
ously (Havlicek et al., 2014). Primary antibodies: anti-PERIPHERIN
(C-19; 1:200; catalog number: SC-7604; Santa Cruz Biotech-
nology), anti-BRN3A (1:200; catalognumber: AB5945;MerckMilli-
pore), anti-TUBULIN (TUJ; 1:300; catalog number: MAB1864;
Merck Millipore), anti-NAV1.5 (1:200; catalog number: ASC-013),
anti-NAV1.9 (1:500; catalog number: ASC-017), and anti-TRPV1
(1:200; catalog number: ACC-030; all Alomone Labs). Images
were acquired using a fluorescence or confocal microscope (Axio
Observer.Z1, Carl Zeiss Microscopy).
Patch-Clamp Experiments of hPSC-Derived
Nociceptors and DRG Cultures
Whole-cell recordings were performed with a HEKA EPC-10USB
amplifier (HEKA electronics) using the following bath solution for
voltage clamp: 140 mM NaCl, 1 mM CaCl2, 1 mMMgCl2, 10 mM
HEPES, 20 mM TEA-Cl, 1 mM 4-Aminopyridin, 0.1 mM CdCl2,
and 10 mM D-glucose (pH 7.4). Glass electrodes (2.0–3.5 MU)
were filled with solution containing 10 mM NaCl, 140 mM CsF,
10 mM HEPES, 1 mM EGTA, 5 mM D-glucose, and 5 mM TEA-Cl
(pH 7.3). For voltage clamp recordings of DRGs, extracellular Na+
was reduced (40mMNaCl, 75mMCholin-Cl), and the internal so-
lution contained 10 mMNaCl, 140 mMCsF, 10 mMHEPES, 1 mM
EGTA, 15 mM D-glucose, and 10 mM TEA-Cl (pH 7.3).
For current clamp experiments the external solution contained
140 mM NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and
10 mM HEPES, (pH 7.4), and internal the solution contained
4 mM NaCl, 135 mM K-gluconate, 3 mM MgCl2, 5 mM EGTA,
5 mM HEPES, 2 mM Na2-ATP, and 0.3 mM Na3-GTP (pH 7.25).
TTX (BIOTREND chemicals) was applied via a gravity-driven
perfusion system or directly added to the bath solution prior to ex-
periments. Capacitive transients were compensated for and leak
(P/4) corrected for using the PatchMaster software (HEKA).
One hundred ms voltage pulses from a holding potential of
120mV(fornociceptors) or90mV(for ratDRGs) toa range ofpo-
tentials in10mVstepsevery5swereusedtogeneratecurrent-voltage
(I-V) curves, which were fitted with a Boltzmann equation: GNa =
GNa,max / 1 + exp [(Vm – Vhalf) / k], where GNa is the sodium conduc-
tance, GNa,max is the maximal sodium conductance, Vhalf is the po-
tential at which activation is half maximal, and k is the slope factor.
Voltage dependence of steady-state fast inactivationwas assessed
by 500 ms steps to various potentials in 10 mV increments fol-
lowed by a test pulse to 20 mV to assess available channels.
Patch-Clamp Experiments on Cell Lines and
Transfected Cells
Cell lines transiently expressing human NAV1.5, NAV1.8, or a
combination of both were patch-clamped using an EPC-10USB312 Stem Cell Reports j Vol. 5 j 305–313 j September 8, 2015 j ª2015 The Aor an Axopatch 200B amplifier and pClamp software (Axon Instru-
ments). Holding potential was 120 mV. The external solution
contained 140 mM NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM MgCl2,
10 mM HEPES, and 10–20 mM D-glucose (pH 7.4). Internal solu-
tion contained 140 mM CsF, 10 mM NaCl, 10 mM HEPES, 1 mM
EGTA, and 15mMD-glucose (pH 7.38). External NaCl was reduced
for recordings of the stable NAV1.5-HEK293 cell line: 70mMNaCl,
70 mM Cholin-Cl, 3 mM KCl, 1 mM CaCl2, 1 mMMgCl2, 10 mM
HEPES, and 20 mMD-glucose (pH 7.4). Internal NaCl was reduced
to 2 mM, and TEA-Cl 10 mM was added to the pipette solution to
improve recording conditions for NAV1.8 in ND7/23 cells.
For TTXr-current isolation, the bath solutions were supple-
mentedwith 500 nMTTX (control) or 5 mMTTX and continuously
superfused during repetitive pulses to 20 mV every 5 s. Currents
were normalized to the mean of the first four test pulses.
All patch-clamp recordingswere performed at room temperature.
Statistics
Statistical analyses were performed in GraphPad Prism version
5.00 or Origin 8.6. Two groups were compared with one-tailed or
two-tailed t tests. Kruskal-Wallis/One-Way ANOVA followed by
Dunn’s or Tukey multiple comparison tests were used when three
or more groups were compared. p values < 0.05 were considered
significant and are indicated as follows: * p < 0.05, ** p < 0.01,
and ****p < 0.0001. All data are shown asmean ± SEMunless other-
wise stated.
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